New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
1,354.94
3.29
+0.24%
Follow LLY
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $26.44 was left as profit. What is an income statement?
| Revenue | 24.4 | 100.0% |
|---|---|---|
| Cost of revenue | −3.9 | −16.1% |
| Gross profit | 20.5 | 83.9% |
| Research & development | −4.2 | −17.4% |
| Selling, general & admin | −3.1 | −12.8% |
| Other operating costs | −4.2 | −17.1% |
| Operating income | 8.9 | 36.5% |
| Other income, net | −0.5 | −2.1% |
| Income tax | −2.0 | −8.0% |
| Net income | 6.5 | 26.4% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $19.3B | $19.8B | $23.0B | $24.4B |
| Operating income | $8.0B | $8.9B | $9.0B | $8.9B |
| Net income | $6.6B | $7.4B | $7.1B | $6.5B |
| Net margin (right axis) | 34.4% | 37.4% | 30.9% | 26.4% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
24,397.00 | 22,974.00 | 19,799.00 | 19,291.00 |
+8 more quarters Free account |
Revenue Growth |
38.61% | 47.67% | 55.54% | 42.55% | |
Cost of Revenue |
3,933.00 | 3,268.00 | 3,577.00 | 3,371.00 | |
Gross Profit |
20,464.00 | 19,706.00 | 16,222.00 | 15,920.00 | |
R&D Expenses |
4,247.00 | 3,819.00 | 3,510.00 | 3,801.00 | |
SG&A Expenses |
3,125.00 | 3,430.00 | 2,934.00 | 3,132.00 | |
Operating Income |
8,911.00 | 8,978.00 | 8,915.00 | 8,010.00 | |
Non-operating Income/Expense |
(505.00) | 269.00 | (65.00) | 255.00 | |
| 8,406.00 | 9,247.00 | 8,850.00 | 8,265.00 | ||
Income Tax Provision |
1,955.00 | 2,152.00 | 1,454.00 | 1,628.00 | |
Income after Tax |
6,451.00 | 7,095.00 | 7,396.00 | 6,637.00 | |
Net Income Common |
6,451.00 | 7,095.00 | 7,396.00 | 6,637.00 | |
EPS (Basic) |
7.22 | 7.94 | 8.26 | 7.39 | |
EPS (Diluted) |
7.22 | 7.94 | 8.26 | 7.39 | |
Shares (Basic, Weighted) |
891.90 | 892.40 | 894.50 | 897.30 | |
Shares (Diluted, Weighted) |
893.40 | 893.70 | 895.90 | 899.30 | |
Gross Margin |
83.88% | 85.78% | 81.93% | 82.53% | |
EBIT Margin |
36.52% | 39.08% | 45.03% | 41.52% | |
EBT margin |
34.46% | 40.25% | 44.70% | 42.84% | |
Net Profit Margin |
26.44% | 30.88% | 37.36% | 34.40% | |
EBITDA |
9,456.00 | 9,512.00 | 9,424.00 | 8,596.00 | |
EBIT |
8,911.00 | 8,978.00 | 8,915.00 | 8,010.00 | |
Income from Continuous Operations |
6,451.00 | 7,095.00 | 7,396.00 | 6,637.00 | |
Consolidated Net Income/Loss |
6,451.00 | 7,095.00 | 7,396.00 | 6,637.00 | |
EPS (Basic, from Continuous Ops) |
7.23 | 7.95 | 8.27 | 7.40 | |
EPS (Diluted, from Cont. Ops) |
7.22 | 7.94 | 8.26 | 7.38 | |
EPS (Basic, Consolidated) |
7.23 | 7.95 | 8.27 | 7.40 | |
EPS (Diluted, Consolidated) |
7.22 | 7.94 | 8.26 | 7.38 | |
Shares (Diluted, Average) |
893.44 | 893.67 | 895.92 | 898.00 | |
EBITDA Margin |
38.76% | 41.40% | 47.60% | 44.56% | |
Operating Cash Flow Margin |
46.71% | 46.53% | 26.94% | 16.72% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026